Kairos Technologies
|
Unmet Medical Need |
Drug |
How Kairos Addresses Unmet Medical Need |
|
Development of resistance to many, otherwise effective cancer drugs |
ENV 105 |
• ENV 105 inhibits CD105 (CD105 is the protein responsible for cancer drug resistance in various forms of cancer) • Currently in Phase 2 trial in prostate cancer and Phase 1 trial in lung cancer |
|
T cells drastically reduced by cancer
|
KROS 101 |
• KROS 101 uses a novel dual mechanism to increase killer T effector cells and reduce suppressor T reg cells (T cells have 2 types cells: those that kill cancer cells and those that inhibit the killer T cell response) |
|
In autoimmune diseases, T cells are overactive against normal cells |
KROS 102 |
• KROS 102 has the opposite effect of KROS101, by decreasing the number of overactive T effector cells and increasing T reg suppressor cells |
|
Immunosuppression from cancer |
KROS 201 |
• KROS 201 are killer T effector cells generated outside of the immunosuppressed body which will be delivered to cancer cells to kill cancer stem cells that drive cancer growth. • Currently cleared for IND (investigational new drug application) by FDA |
|
Chemotherapies are untargeted and immunosuppressive |
KROS 301 |
• KROS 301 kills tumor cells while leaving normal cells unscathed by targeting the NF-kB molecular pathway. KROS 301 also inhibits the mechanism of PD-L1 expression on tumor cells (PD-L1 is a “checkpoint inhibitor” that prevents T cells from killing the cancer) |
|
Tumor environment is immunosuppressive from macrophages (a type of white cell that can be either anti-cancer or pro-cancer) |
KROS 401 |
• KROS 401 targets pro-cancer macrophages to convert them into anti-cancer macrophages |
|
Development of resistance to various specific chemotherapies |
ENV 205 |
• ENV 205 targets & expels mitochondrial DNA that are released by tumors which use this mechanism of resistance against specific chemotherapies |